This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market. The report assesses how these players will be insulated from the impact of generic competition as a result of mAb market penetration.
Scope
Provides in-depth analysis (including sales forecasts to 2012) of key players within the mAb market.
Assesses the strategic decisions which have been implemented by key mAb market players.
Provides an overview of mAb market business models and alliance networks.
Outlines the key therapeutic segments within the mAb market where key players operate.
Report Highlights Over the period 200612, monoclonal antibodies (mAbs) are forecast to act as the key growth segment of the prescription pharmaceutical market. mAb revenues are anticipated to grow at a compound annual growth rate of 14.2% over the period 200612, versus 2.2% for the overall market.
Four players currently hold a dominant position in the global mAb market: Genentech, Roche, Johnson & Johnson and Abbott, accounting for a combined 74.8% share of mAb market revenues.
However, Datamonitor forecasts that by 2012 a number of additional players will have significantly enhanced their presence in the mAb segment, with four companiesBiogen IDEC, Amgen, Novartis and UCB Pharmaeach forecast to generate mAb sales growth in excess of $1 billion.
Reasons to Purchase
Understand in detail the dynamics of mAb market growth over 2006-12, which will be driven by four 'established' players and four 'emerging' players.
Assess how penetration of the mAb market will provide companies with increased insulation from the impact of generic competition.
Analyze the factors that have driven the evolution and commercial expansion of the mAb market, and those that will drive future sales growth.
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
